1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Zhong Yuan Bio-Technology Holdings Limited

Zhong Yuan Bio-Technology Holdings Limited

ZHYBF
Zhong Yuan Bio-Technology Holdings LimitedUS flagOther OTC
2.02
USD
- -
- -
35.75MMarket Cap
Zhong Yuan Bio-Technology Holdings Limited
ZHYBF
(Other OTC)

Recent

price

2.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
- -
- -
- -
0.07
0.07
0.1
0.13
0.09
- -
Revenue per Share
- -
- -
- -
0.02
-0.01
- -
-0.07
-0.12
- -
Basic EPS, GAAP
- -
- -
- -
0.04
-0.01
0.02
-0.01
-0.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
-0.01
-0.01
-0.01
-0.08
-0.2
- -
Book Value per Share
- -
- -
- -
0.08
0.09
0.09
0.05
-0.04
- -
Tangible Book Value per Share
- -
17
17
17
17
17
17
18
- -
Basic Weighted Avg Shares
- -
- -
- -
1
1
2
2
2
2
Sales/Revenue/Turnover
- -
- -
- -
25.64
-7.01
-0.89
-27.44
-93.11
14.77
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
-1
-2
- -
Net Income, GAAP
- -
- -
- -
5.37
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
23.01
-7.16
-1.71
-48.34
-129.27
13.27
Profit Margin (%)
- -
- -
- -
1
1
2
1
-1
- -
Working Capital
- -
- -
- -
- -
- -
1
1
1
1
LT Debt
- -
- -
- -
1
1
2
1
-1
- -
Total Equity
- -
- -
- -
36.76
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
3,772.05
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-54.87%
-67.93%
Free Cash Flow
- -
-63.97%
-28.82%
Net Income, GAAP
- -
738.91%
-114.06%
Sales/Revenue/Turnover
- -
17.01%
37.03%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
2
2023
- -
- -
- -
- -
2
2024
- -
- -
- -
- -
2

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.07
2023
- -
- -
- -
- -
-0.12
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Vital KSK Holdings, Inc. (3151.T)
AS ONE Corporation (IUSDF)
Alfresa Holdings Corporation (2784.T)
Charmacy Pharmaceutical Co., Ltd. (2289.HK)
PT Enseval Putera Megatrading Tbk. (EPMT.JK)
Tai United Holdings Limited (0718.HK)
Business
Zhong Yuan Bio-Technology Holdings Limited centers its operations on the advancement and commercialization of health solutions rooted in nervonic acid, primarily within the Chinese market. The company provides a range of offerings, including specialized nervonic acid oils and formulas derived from Acer truncatum, as well as nutritional candies designed for brain health support. Beyond dietary supplements, it also develops diagnostic kits for neurological conditions, with a cognitive impairment screening kit currently undergoing preclinical trials. Furthermore, Zhong Yuan Bio-Technology actively engages in extensive research and development for new pharmaceutical interventions targeting neurological disorders such as Alzheimer's, Parkinson's, and ADHD. The firm leverages its substantial resources, including extensive Acer truncatum plantations, to support its product pipeline and research endeavors, operating under brands like Muzhiyuan-Neuro Enhancer. Based in Wanchai, Hong Kong, the company is committed to delivering comprehensive brain health solutions from detection to treatment.